Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Kepivance Launch Under Way At Price Of $1,375 Per Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

Mucositis therapy will have an initial market of less than $50 mil. for first approved indication, but potential for use in broader cancer market would be $3 bil. opportunity. Kepivance will help Amgen build on position as number one oncology company in U.S., although Amgen is cautioning investors to expect slower growth in 2005 in light of reimbursement climate.

You may also be interested in...



Amgen Raises Profile Of Oncology Therapeutics Unit

Newly promoted VP David Parkinson, MD, will oversee reconfigured oncology unit with separate supportive care and therapeutics groups.

Amgen Raises Profile Of Oncology Therapeutics Unit

Newly promoted VP David Parkinson, MD, will oversee reconfigured oncology unit with separate supportive care and therapeutics groups.

MGI To File Saforis NDA For Oral Mucositis By October

The company plans to file the fast-track NDA based on the results of one Phase III trial. A second trial will be initiated after the filing in order to expand the market potential and support a European filing, MGI says.

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel